2025 Q4 -tulosraportti
16 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | NON | NON | ||
| 5 000 | NON | NON | ||
| 295 | NON | NON | ||
| 181 | NON | NON | ||
| 1 488 | NON | NON |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten
·1 päivä sittenDeals with a solution regarding entrepreneurs and listed companies: “Curasight's accounting equity is admittedly only 18 mio. kr. and would therefore not be enough for Krasilnikoff, with an ownership stake of 11,6 pct., to pay wealth tax. But since the shares are listed, they will, according to experts, in all likelihood – in the event of wealth tax – have to be valued at market value, also in a tax context. Regardless of Mette Frederiksen's promise.”
·1 päivä sitten · MuokattuI've been working a bit on an analysis of the Curasight case and where I think it's headed. Curasight is not a classic biotech case: as it will either be very expensive… or it will be a little less expensive ..💎 The entire case depends on one data point: Phase I data from uTREAT in 3-4 months. Radioligand therapy is currently an area where Big Pharma buys targets almost as fast as investors buy hope. In the analysis, I estimate: - approx. 70 % probability of success in Phase I (conservatively) - a realistic strategic exit of 5-9 billion USD (with upside) - Big Pharma has bought the uPAR platform before Christmas (at the latest) Yep, that sounds intense, but the case IS also intense....! 😊 You can read the analysis here, if you like…. https://drive.google.com/file/d/1TORx_xv0n4HBHffR8mlzeq-KhYZVtG2y/view?usp=sharing Data is King – we need to see it! Disclaimer: not an analysis for people with high blood pressure, delicate nerves or a tendency to follow the daily share price.......and also a warning to the 'old school' folks - IA has been used – lots of AI 🤣!
·2 päivää sittenNow that it's a bit quiet in here, it would be fun to hear which stocks you otherwise hold or see potential in going forward 😊 I personally bought into the following a few weeks ago, which I find very exciting: Circio as well as Ascelia Pharma
·2 päivää sittenwhy is it falling
·2 päivää sittenWhy is it rising? ;) NOTE irony. A stock both falls and rises in intervals for no reason at all sometimes and that is completely normal. The basic principle is supply and demand. Market psychology plays a role. News and rumors can make the stock both rise and fall. In Curasight's case, it could be the debt conversion that affects it a little (dilution). Look at a stock long-term to get an idea of movements. This will be my short answer- ·3 päivää sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
16 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten·1 päivä sittenDeals with a solution regarding entrepreneurs and listed companies: “Curasight's accounting equity is admittedly only 18 mio. kr. and would therefore not be enough for Krasilnikoff, with an ownership stake of 11,6 pct., to pay wealth tax. But since the shares are listed, they will, according to experts, in all likelihood – in the event of wealth tax – have to be valued at market value, also in a tax context. Regardless of Mette Frederiksen's promise.”
- ·1 päivä sitten · MuokattuI've been working a bit on an analysis of the Curasight case and where I think it's headed. Curasight is not a classic biotech case: as it will either be very expensive… or it will be a little less expensive ..💎 The entire case depends on one data point: Phase I data from uTREAT in 3-4 months. Radioligand therapy is currently an area where Big Pharma buys targets almost as fast as investors buy hope. In the analysis, I estimate: - approx. 70 % probability of success in Phase I (conservatively) - a realistic strategic exit of 5-9 billion USD (with upside) - Big Pharma has bought the uPAR platform before Christmas (at the latest) Yep, that sounds intense, but the case IS also intense....! 😊 You can read the analysis here, if you like…. https://drive.google.com/file/d/1TORx_xv0n4HBHffR8mlzeq-KhYZVtG2y/view?usp=sharing Data is King – we need to see it! Disclaimer: not an analysis for people with high blood pressure, delicate nerves or a tendency to follow the daily share price.......and also a warning to the 'old school' folks - IA has been used – lots of AI 🤣!
- ·2 päivää sittenNow that it's a bit quiet in here, it would be fun to hear which stocks you otherwise hold or see potential in going forward 😊 I personally bought into the following a few weeks ago, which I find very exciting: Circio as well as Ascelia Pharma
- ·2 päivää sittenwhy is it falling·2 päivää sittenWhy is it rising? ;) NOTE irony. A stock both falls and rises in intervals for no reason at all sometimes and that is completely normal. The basic principle is supply and demand. Market psychology plays a role. News and rumors can make the stock both rise and fall. In Curasight's case, it could be the debt conversion that affects it a little (dilution). Look at a stock long-term to get an idea of movements. This will be my short answer
- ·3 päivää sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | NON | NON | ||
| 5 000 | NON | NON | ||
| 295 | NON | NON | ||
| 181 | NON | NON | ||
| 1 488 | NON | NON |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
16 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten·1 päivä sittenDeals with a solution regarding entrepreneurs and listed companies: “Curasight's accounting equity is admittedly only 18 mio. kr. and would therefore not be enough for Krasilnikoff, with an ownership stake of 11,6 pct., to pay wealth tax. But since the shares are listed, they will, according to experts, in all likelihood – in the event of wealth tax – have to be valued at market value, also in a tax context. Regardless of Mette Frederiksen's promise.”
- ·1 päivä sitten · MuokattuI've been working a bit on an analysis of the Curasight case and where I think it's headed. Curasight is not a classic biotech case: as it will either be very expensive… or it will be a little less expensive ..💎 The entire case depends on one data point: Phase I data from uTREAT in 3-4 months. Radioligand therapy is currently an area where Big Pharma buys targets almost as fast as investors buy hope. In the analysis, I estimate: - approx. 70 % probability of success in Phase I (conservatively) - a realistic strategic exit of 5-9 billion USD (with upside) - Big Pharma has bought the uPAR platform before Christmas (at the latest) Yep, that sounds intense, but the case IS also intense....! 😊 You can read the analysis here, if you like…. https://drive.google.com/file/d/1TORx_xv0n4HBHffR8mlzeq-KhYZVtG2y/view?usp=sharing Data is King – we need to see it! Disclaimer: not an analysis for people with high blood pressure, delicate nerves or a tendency to follow the daily share price.......and also a warning to the 'old school' folks - IA has been used – lots of AI 🤣!
- ·2 päivää sittenNow that it's a bit quiet in here, it would be fun to hear which stocks you otherwise hold or see potential in going forward 😊 I personally bought into the following a few weeks ago, which I find very exciting: Circio as well as Ascelia Pharma
- ·2 päivää sittenwhy is it falling·2 päivää sittenWhy is it rising? ;) NOTE irony. A stock both falls and rises in intervals for no reason at all sometimes and that is completely normal. The basic principle is supply and demand. Market psychology plays a role. News and rumors can make the stock both rise and fall. In Curasight's case, it could be the debt conversion that affects it a little (dilution). Look at a stock long-term to get an idea of movements. This will be my short answer
- ·3 päivää sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | NON | NON | ||
| 5 000 | NON | NON | ||
| 295 | NON | NON | ||
| 181 | NON | NON | ||
| 1 488 | NON | NON |
Välittäjätilasto
Dataa ei löytynyt